Global Health Institute
In line with our corporate responsibility, the company is committed to improving the health of underserved populations that lack access to health solutions including prevention, diagnostics and therapy.
Through science and technology innovation, the Institute is mandated to impact in a sustainable manner to the worldwide Global Health Agenda for the Company by strengthening control of infectious diseases as well as contributing to elimination agendas.
The Institute is working to address key unmet medical needs related to infectious diseases.
The goal is to develop and provide access to transformative health solutions for the most vulnerable populations (children and women) in low-and-middle-income countries. Focus is on schistosomiasis, malaria and anti-microbial resistance (AMR).
The Global Health Institute defines and implements an integrated strategy to develop and deliver health solutions that address major global health challenges.
The approach covers:
- Treatments for high unmet medical needs
- Detection focusing on highly sensitive and specific diagnostic methods
- Transmission controls for developing products and technologies to improve preventive measures
- Methods & tools to strengthen health systems through technologies and education programs.
Our operating model
The Global Health Institute operates through a social business model that aims to ensure sustainability, affordability and availability of final products and services.
It consists of a non-maximizing profit model to increase impact and ensuring financial sustainability.
The Institute also applies the shared value concept which combines its focus on both societal and economic progress.
The model is based on public-private partnerships with leading global health institutions/organizations in both developed and developing countries.
The Institute has built up, broadened and advanced a comprehensive portfolio, including the following programs:
- Development of a pediatric Praziquantel (PZQ) formulation to treat schistosomiasis in children under the age of six
- Development of a new active ingredient for the treatment and prevention of malaria in very young children
- Screening programs through dedicated drug discovery platforms for new potential candidates against schistosomiasis and malaria
- Development of diagnostics for schistosomiasis and for malaria
- Development of products and technologies to improve preventive measures
The Institute’s structure, integrated strategy and operating model as well as its portfolio showcases the Company’s continuous engagement in the fight against infectious diseases, to improve health for all.
The Access to Medicines Index 2018 report published in November 2018 highlights the Institute as a leading practice to accelerate R&D, incorporate access provisions and build capacity for projects and initiatives targeting schistosomiasis, malaria and other infections.
WORLD MALARIA DAY: Zero Malaria starts with us
Infectious diseases like malaria have a severe impact on health systems. As “one against malaria”, we support epidemiological surveillance research network in Africa to make health systems more resilient.
Global Health Institute (Merck KGaA, Darmstadt, Germany)More information
Global Health Institute (Merck KGaA, Darmstadt, Germany)
The Institute develops and provides access to integrated health solutions for children and women to address major global health challenges.
Consortium Pediatric Praziquantel ProgramMore information
Consortium Pediatric Praziquantel Program
The Pediatric Praziquantel Consortium is an international public-private partnership that aims to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children (below 6 years of age).
The Integrated Malaria ProgramMore information
The Integrated Malaria Program
Effective control of malaria requires an integrated approach. The Malaria program aims to develop treatments, diagnostics as well as vector control methods; it also seeks to strengthen health systems through research initiatives and educational programs in and for developing countries.